B-Cell Lymphoma

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial.

A real-world evaluation of axicabtagene ciloleucel for individuals with relapsed or refractory large B-cell lymphoma showed 5-year OS, PFS and disease-specific survival rates comparable to those observed in clinical trials.

Second-line therapy with axicabtagene ciloleucel induced a complete metabolic response in 71% of adults with relapsed or refractory large B-cell lymphoma ineligible for autologous stem cell transplant, results of a phase 2 study showed.

The addition of metformin to standard chemotherapy improved outcomes for patients with diffuse large B-cell lymphoma, according to findings presented at Society of Hematologic Oncology Annual Meeting.

CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated high-risk diffuse large B-cell lymphoma and double-hit or triple-hit lymphoma, according to research presented at ASCO Annual Meeting.

CHICAGO — In this video, Emanuele Zucca, MD, discusses the IELSG37 trial supporting the omission of mediastinal radiotherapy in patients with primary mediastinal B-cell lymphoma who achieve complete metabolic response after chemotherapy.

CHICAGO — Negative circulating tumor DNA status contributed to a PFS benefit for patients with previously untreated diffuse large B-cell lymphoma, according to research presented at ASCO Annual Meeting.

The FDA granted accelerated approval to glofitamab-gxbm for treatment of certain adults with relapsed or refractory diffuse large B-cell lymphoma.

CHICAGO — Radiation therapy can be safely omitted for patients with primary mediastinal B-cell lymphoma who demonstrate a complete metabolic response after chemoimmunotherapy, according to data presented at ASCO Annual Meeting.

CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.